You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Business & Finance
Premier Expands Effort to Supply Shortage Generic Drugs
14 January 2019 - - US-based healthcare improvement company Premier Inc. (NASDAQ: PINC) has established a company to help ensure health systems have continuous and affordable access to shortage medications, as well as those in categories that lack competition, the company said.
The company builds on Premier's eight-year track record of direct contracting for healthcare supplies and extends existing programmes that are successfully providing uninterrupted access to more than 91 shortage stock keeping units.
This new company, ProvideGx, provides a vehicle for Premier to invest in innovative new business models and partnerships to address drug shortages, including partnering with quality generic drug manufacturers that can supply shortage products, co-funding the development of affordable products that address specific market needs, and securing contracts for active pharmaceutical ingredients to ensure a continuous supply as well as strategic sourcing agreements.
ProvideGx has already partnered with five generic manufacturers to address a targeted pipeline of 60 crucial drugs, and expects to begin marketing additional shortage products next month, pending approval by the US Food and Drug Administration.
According to the University of Utah Drug Information Service, 224 vital medications are in current shortage nationwide, including antimicrobials, cardiovascular drugs, sedation medications, electrolytes, nutritional supplements and chemotherapy drugs.
As a result of these persistent shortages, 96% of health systems report that securing an adequate source of supply is a near constant challenge.
ProvideGx is guided by 31 Premier member health systems and the company's National Pharmacy Committee, representing more than 1,000 hospitals across the nation.
Revenues from the new company are not expected to materially impact Premier FY 2019 results.
Premier Inc. (NASDAQ: PINC) is a healthcare improvement company, uniting an alliance of more than 4,000 US hospitals and health systems and approximately 165,000 other providers and organizations to transform healthcare.
The company builds on Premier's eight-year track record of direct contracting for healthcare supplies and extends existing programmes that are successfully providing uninterrupted access to more than 91 shortage stock keeping units.
This new company, ProvideGx, provides a vehicle for Premier to invest in innovative new business models and partnerships to address drug shortages, including partnering with quality generic drug manufacturers that can supply shortage products, co-funding the development of affordable products that address specific market needs, and securing contracts for active pharmaceutical ingredients to ensure a continuous supply as well as strategic sourcing agreements.
ProvideGx has already partnered with five generic manufacturers to address a targeted pipeline of 60 crucial drugs, and expects to begin marketing additional shortage products next month, pending approval by the US Food and Drug Administration.
According to the University of Utah Drug Information Service, 224 vital medications are in current shortage nationwide, including antimicrobials, cardiovascular drugs, sedation medications, electrolytes, nutritional supplements and chemotherapy drugs.
As a result of these persistent shortages, 96% of health systems report that securing an adequate source of supply is a near constant challenge.
ProvideGx is guided by 31 Premier member health systems and the company's National Pharmacy Committee, representing more than 1,000 hospitals across the nation.
Revenues from the new company are not expected to materially impact Premier FY 2019 results.
Premier Inc. (NASDAQ: PINC) is a healthcare improvement company, uniting an alliance of more than 4,000 US hospitals and health systems and approximately 165,000 other providers and organizations to transform healthcare.
Login
Related Headlines
Danaher Corporation announces quarterly cash dividend
Abbott announces quarterly common dividend
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva